Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
It has been shown in previous studies that the ability to treat lung cancer could be
significantly improved by not only targeting the tumor cells directly with chemotherapy, but
also by cutting off the blood supply to the cancer cells. Blood vessels that supply the tumor
are formed through a process called angiogenesis. Vandetanib is an investigational drug that
acts by producing what is called an anti-angiogenic effect. An Anti-angiogenic effect is able
to inhibit the development of new blood vessels required by tumors to survive by blocking the
growth factors needed to form new blood vessels.
The purpose of this study is to determine if the addition of vandetanib to a standard
chemotherapy regimen will slow or stop the growth of the cancer for a longer period of time
compared to the time period generally gained from the use of standard chemotherapy alone